Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04020276 · ClinicalTrials.gov registry record · NA
OAR-Based, Dose Escalated SBRT With Real Time Adaptive MRI Guidance for Liver Metastases
A NA study of Liver Metastases and Stereotactic Body Radiation Therapy, sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- NA
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT04020276 is a NA study of Liver Metastases and Stereotactic Body Radiation Therapy that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 32 participants, below the 67-participant average among 27 other Liver Metastases trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04020276, a NA study of Liver Metastases and Stereotactic Body Radiation Therapy, is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this trial is to identify a safe maximum tolerated dose level for MRI-guided Stereotactic Body Radiation Therapy (SBRT) treatment of bowel and liver metastases, respectively. Eligible participants will be on study for up to 12 months.
Conditions Studied
Interventions
- RADIATION SBRT
Study Locations (1)
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2019-11-04 |
| Est. Completion | 2028-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04020276
The ClinicalTrials.gov registry entry for NCT04020276 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 67-participant average among 27 other Liver Metastases trials with a reported enrollment target (52% lower). The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Liver Metastases appearing as the primary indexed condition, and to 1 intervention - of which SBRT is the first listed.
NCT04020276 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT04020276 about?
NCT04020276 is a clinical study titled "OAR-Based, Dose Escalated SBRT With Real Time Adaptive MRI Guidance for Liver Metastases". The purpose of this trial is to identify a safe maximum tolerated dose level for MRI-guided Stereotactic Body Radiation Therapy (SBRT) treatment of bowel and liver metastases, respectively. Eligible participants will be on study for up to 12 months.
What is the current status of trial NCT04020276?
This trial is currently recruiting. It is a NA study. The enrollment target is 32 participants. The study started on 2019-11-04. Estimated completion is 2028-12.
What conditions does trial NCT04020276 study?
This clinical trial studies the following conditions: Liver Metastases, Stereotactic Body Radiation Therapy, MRI-guided Treatment.
What interventions are being tested in trial NCT04020276?
The interventions under investigation include: SBRT (RADIATION).
Who is sponsoring clinical trial NCT04020276?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04020276 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Promoting Immunotherapy Efficacy With Low-Dose Liver RT
RECRUITING · NA
-
Stereotactic Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis
RECRUITING · NA
-
HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer
RECRUITING · NA
-
Proton Therapy in the Treatment of Liver Metastases
RECRUITING · NA
-
Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer
ACTIVE NOT RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.